The United States Pharmacopeia provides standards for safely handling hazardous drugs, and the organization has announced USP General Chapter <800> with new guidelines for health care professionals who handle hazardous drugs. The chapter is expected to become official in December 2019. Spironolactone tablets are listed as hazardous by NIOSH, so they require special handling practices. However, CaroSpir is a liquid oral suspension of spironolactone that does not appear on the NIOSH list of hazardous drugs and does not have a black box warning. The guidelines for handling hazardous drugs like spironolactone tablets do not apply to CaroSpir.
Read more about the upcoming guidelines in this article from www.USP.org
CaroSpir is the first and only FDA-approved oral suspension of the potassium-sparing diuretic spironolactone. Visit www.CaroSpir.com to learn more.